Gilead Sciences Inc (GILD) is a publicly traded drug manufacturers-general business based in the US. It opened the day at $62.51 after a previous close of $62.86. During the day the price has varied from a low of $62.165 to a high of $62.925. The latest price was $62.34 (25 minute delay). Gilead Sciences is listed on the NASDAQ and employs 14,400 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
Referral bonus
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £2.88 £578.96 total |
Capital at risk |
|
£0 | £250 | £12.17 £588.25 total |
Capital at risk |
|
£0 | No minimum | £5.76 £581.84 total |
Capital at risk |
 |
£0 | £1 | £17.71 £593.79 total |
Capital at risk |
 |
£0 | £0.01 | £0.58 £576.66 total |
Capital at risk |
 |
£0 | £1 | £2.59 £578.68 total |
Capital at risk |
 |
£9.99 per month | No minimum | £16.63 £592.72 total |
Capital at risk |
 |
£0 | £50 | £2.88 £578.96 total |
Capital at risk |
 |
£36 per year | £20 | £16.70 £592.78 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of $62.34
| 1 week (2022-09-20) | -3.47% |
|---|---|
| 1 month (2022-08-26) | -0.05% |
| 3 months (2022-06-27) | -0.78% |
| 2 years (2020-09-25) | 0.14% |
|---|---|
| 3 years (2019-09-27) | -0.89% |
| 5 years (2017-09-27) | -25.66% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Gilead Sciences shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Gilead Sciences's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5518. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Gilead Sciences's PEG ratio in relation to those of similar companies.
Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $13.2 billion (£12.2 billion).
The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.
Gilead Sciences's total ESG risk: 22.15
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 01/01/2019) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Gilead Sciences's total ESG risk score against those of similar companies.
Gilead Sciences's environmental score: 0.53/100
Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Gilead Sciences's social score: 12.97/100
Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Gilead Sciences's governance score: 7.65/100
Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Gilead Sciences's controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
Gilead Sciences Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.15 |
|---|---|
| Total ESG percentile | 30.98 |
| Environmental score | 0.53 |
| Environmental score percentile | 2 |
| Social score | 12.97 |
| Social score percentile | 2 |
| Governance score | 7.65 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
| Open | $62.51 |
|---|---|
| High | $62.925 |
| Low | $62.165 |
| Close | $62.34 |
| Previous close | $62.86 |
| Change | $-0.52 |
| Change % | -0.8272% |
| Volume | 5,866,183 |
| 52-week range | $55.2732 - $71.4734 |
|---|---|
| 50-day moving average | $63.0878 |
| 200-day moving average | $63.8468 |
| Wall St. target price | $70.78 |
| PE ratio | 20.1284 |
| Dividend yield | $2.88 (4.44%) |
| Earnings per share (TTM) | $3.27 |
Dividend yield: 4.44% of stock value
Forward annual dividend yield: 4.44% of stock value
Dividend payout ratio: 41.19% of net profits
Gilead Sciences has recently paid out dividends equivalent to 4.44% of its share value annually.
Gilead Sciences has paid out, on average, around 41.19% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.44% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 4.44% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $2.88 per share.
While Gilead Sciences's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Gilead Sciences's most recent dividend payout was on 29 September 2022. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2022 (the "ex-dividend date").
Gilead Sciences's dividend yield is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $55.2732 up to $71.4734. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.328. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).
To put Gilead Sciences's beta into context you can compare it against those of similar companies.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
